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ABSTRACT 
In the last ten years, the field of proteomics has expanded at a rapid rate. A range of exciting 
new technology has been developed and enthusiastically applied to an enormous variety of 
biological questions. However, the degree of stringency required in proteomic data 
generation and analysis appears to have been underestimated. As a result, there are likely to 
be numerous published findings 
that are of questionable quality, requiring further confirmation and/or validation. This 
manuscript outlines a number of key issues in proteomic research, including those associated 
with experimental design, differential display and biomarker discovery, protein identification 
and analytical incompleteness. In an effort to set a standard that reflects current thinking on 
the necessary and desirable characteristics of publishable manuscripts in the field, a minimal 
set of guidelines for proteomics research is then described. These guidelines will serve as a 
set of criteria which editors of PROTEOMICS will use for assessment of future submissions 
to the Journal. 
 
 
INTRODUCTION 
Proteomics by name is now over 10 years old [1, 2] and many of the key technological 
innovations that made proteomics possible are of a similar or greater age. MS-based protein 
identification using PMF or LC-MS/MS [3–5] is now widely 
adopted, and the transition from analysing one protein at a time to analysing highly complex 
mixtures has been made [6, 7]. For semi-quantitative analyses and comparisons, the 
proteomics researcher now has access to a variety of sophisticated techniques, including mass 
spectrometric approaches combined with stable isotopic labelling [7–11] and 2-D gel-based 
approaches combined with differential staining [12] or traditional visualisation and 
comparison techniques. The 
variety of methods for the characterisation of protein co- and post-translational modifications 
is ever-expanding [12, 13], as are the means of elucidating protein-protein interactions [15–
17]. The field of proteomics has grown at an astonishing 
rate, and shows no sign of slowing. If anything, it appears to be gaining momentum as 
proteomic techniques become increasingly widespread and applied to an expanding 
smorgasbord of biological questions. The rapid expansion of proteomics, whilst exciting, has 
brought with it many technical issues. In some areas, it could be argued that we began to run 
before we could walk. New but immature technology has been enthusiastically applied to 
significant biological questions, and the results have become part of the scientific literature 
and databases. However, the degree of stringency required in proteomic data generation and 
analysis appears to have been underestimated. As a result, there are likely to be numerous 
published findings that are of questionable quality, requiring further confirmation and/or 
validation. For the future, a number of key but intersecting areas of concern can be identified, 
which if addressed should help improve the quality of proteomic research. These are 
discussed briefly below. 
 
 
EXPERIMENTAL DESIGN 
Proteomic techniques such as 2-D PAGE and shotgun proteomics (MudPIT/ICAT/iTRAQ) 
are powerful means of generating analytical data [6, 7, 11]. This analytical information is 
used to understand the nuances of the proteome of a biological 
system, and in many cases is the basis of comparison of two or more samples. Yet the 
technical difficulty and high cost of data production, associated with highly time-consuming 
data analysis, has contributed to a position where poor experimental design is common. Many 
experiments that use 2-D PAGE have a low number of analytical and/or biological replicates, 
and users of MS differential display often assume that multiple estimates of differences 
generated by a single ICAT/iTRAQ experiment provide a substitute for experimental 
replicates. The reproducibility of 
proteomic techniques used, as assayed by regression analysis, co-efficient of variation or 
other variance estimation techniques [18], is typically not reported. Power analyses, which 
can be used to infer the number of samples that should be analysed to discover a statistically 
significant result [18–20], are rarely undertaken. Weak experimental designs, particularly in a 
field where technical challenges remain in the production of high quality data, can make it 
difficult or impossible to determine if differences reported between two or more samples are 
likely to reflect variation in a biological system or are solely analytically derived. 
 
 
DIFFERENTIAL DISPLAY AND BIOMARKER DISCOVERY 
Proteomic techniques are frequently used for the discovery of differentially expressed 
proteins, including biomarkers. 
These techniques can be used in a hypothesis-independent manner, making them attractive 
for this purpose. Whilst statistical tests are being increasingly applied to protein expression 
data, proteins are frequently published as differentially expressed on the basis of a two-fold 
or greater expression difference. Such conclusions ignore the analytical and biological 
variation inherent to any laboratory and the samples under study. It is also not infrequent to 
see proteins described as differentially expressed from use of univariate statistical tests (e.g. 
Student’s t-test), but where the normal distribution of the data has been assumed but not 
tested. 
This is of great concern as proteomic expression data is typically not normally distributed but 
is skewed, and requires transformation before many statistical tests can be applied [18, 21]. 
After appropriate statistical analysis, it may come to pass that a two-fold expression 
difference is shown to be significant for a particular protein. However, it is only through the 
detailed analysis of expression data, involving data normalisation, appropriate 
transformation, determination of the 
inherent variance and the use of suitable uni- and multivariate statistical tests, that this can be 
resolved. 
 
PROTEIN IDENTIFICATION 
The issue of erroneous protein identification is widely appreciated, and has been the subject 
of detailed discussion elsewhere [22]. Fortunately, the identification of individual proteins by 
PMF or LC-MS/MS is increasingly well supported by statistical scoring systems in tools [23–
25], which greatly assists in the assignment of high confidence identifications. 
For single or small groups of proteins, research  manuscripts can also include relevant spectra 
or mass data, allowing for independent confirmation of identification results. By comparison, 
major issues remain in the identification of proteins from large-scale, automated experiments 
that analyse proteins via LC-MS/MS or LC-LC-MS/MS. Nonsystematic use of scoring 
cutoffs, that assess the number of peptides matching a protein and/or the quality of the match, 
can dramatically change the numbers of proteins deemed to have been identified from a 
complex sample [26, 27]. In some cases, protein identities are made on the basis of a match 
between one fragmented peptide and a database entry. 
Clearly, ongoing vigilance will be required in this area, to minimise the misinterpretation of 
these complex data. 
 
 
ANALYTICAL INCOMPLETENESS 
Analytical incompleteness refers to a phenomenon where a technique used for the analysis of 
complex mixtures of peptides may only yield information for a fraction of relevant peptides 
in any single analytical run. For example, it has been observed that two replicate MudPIT 
analyses will produce two sets of protein identifications with ,65% overlap [28, 29]. Thirty-
five percent of the proteins in the second analysis are likely to be novel compared to the first. 
A third replicate MudPIT analysis is likely to yield a set of identifications that has 80% 
overlap with those from the first two analyses, but with 20% new identifications. Because of 
the differences in proteins seen per run, it has been estimated that 10 to 12 MudPIT analyses 
may be necessary before a near-complete list of protein identities is generated from a single 
complex sample [28, 29]. This phenomenon has a substantial impact on use of LC-LC-
MS/MS for qualitative biomarker discovery or differential display experiments, as the 
presence or absence of a protein in a particular run may 
reflect analytical incompleteness instead of true differences between samples. Accordingly, 
the comprehensive comparison of two or more proteomes by these approaches will require 
great care and high numbers of replicates [30]. It should finally be noted that analytical 
completeness is also inherent to the technique of 2-D PAGE, where it can arise from 
inconsistent sample loading and staining, leading to differences in the numbers of proteins 
detected in gel images [31]. However the paradigm of differential display via 2-D PAGE 
typically identifies proteins of interest only after statistical expression analysis, making this a 
less pressing issue. 
 
MOVING TOWARDS NEW GUIDELINES 
In the context of the above concerns, the authors of this article initiated a process to develop a 
set of minimum guidelines for the field, which could assist researchers in the execution of 
proteomics experiments and in the drafting of their manuscripts. It was intended to serve as a 
set of criteria which editors of PROTEOMICS could use for assessment of submissions, and 
to set a standard that reflects current thinking on the necessary and desirable characteristics of 
publishable manuscripts in the field. A set of 19 issues were identified from a broad-ranging 
discussion between the authors, who together have extensive experience in the development 
of proteomic technology (including bioinformatics) and its application to academic and 
industrial biomedical research. Each issue was drafted into a one-page working document. 
Reference was made to journals that publish gene expression analysis experiments, which 
have faced similar experimental design and data analysis issues. In July 2005 the Editors of 
PROTEOMICS were represented 
at a workshop initiated by the journal of Molecular and Cellular Proteomics (MCP), which 
primarily sought to develop standards for preparing, reviewing and publishing of data from 
MS/MS experiments. Finally, a round-table meeting of 
the authors of this document was held at the 4th HUPO conference in August 2005 to 
consider each issue, the outcomes of the MCP workshop, and other relevant discussion 
documents [22, 32]. The final set of guidelines, in the addendum to this document, is the 
result of this process. 
Our aim has been to produce a set of guidelines that are brief and precise, that are easy to 
understand and not overly onerous to follow. We believe that the guidelines are 
selfexplanatory and do not require further discussion here. With the constant changes in 
technology, and the evolution of standard practices and means of data sharing in the 
proteomics community [33], we expect that these guidelines will 
require updating from time to time. We welcome any thoughts or comments on this first set 
of guidelines and how they can be improved, and look forward to ongoing discussion with all 
proteomics researchers on this important issue. 
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ADDENDUM 
 
Editorial and Author Guidelines for Publication in 
PROTEOMICS 
 
These guidelines outline issues that authors must follow when submitting a paper for 
publication in PROTEOMICS. Failure to follow these guidelines may be grounds for an 
Editorial decision to reject a manuscript without review. 
Authors are also requested to take note of the different types of manuscripts that are suitable 
for PROTEOMICS as detailed in the ‘Instructions to Authors’. 
 
Experimental design and data analysis for 2-D PAGE and MS-based experiments 
– The experimental design must be provided and must include details of the number of 
biological and analytical replicates. Only one biological/analytical replicate will not be 
acceptable. In clinical studies, it is highly desirable that a power analysis predicting the 
appropriate sample size for subsequent statistical analysis of the data is carried out. 
 
– For expression analysis studies, summary statistics (mean, standard deviation) must be 
provided and results of statistical analysis must be shown. Reporting fold differences alone is 
not acceptable. Authors must report the following: methods of data normalization, 
transformation, missing value handling, the statistical tests used, the degrees of freedom and 
the statistical package or program used. Where biologically important differences in protein 
(gene) expression are reported, confirmatory data (e.g. from immunoassays) are desirable. 
 
– For biomarker discovery/validation studies, the sensitivity and specificity of the 
biomarker(s) should be provided wherever possible. It is desirable that receiver operator 
characteristic (ROC) curves and areas under the curves are given. 
 
 
Protein identification and characterization 
 
– The method(s) used to generate the mass spectrometry data must be described, as should 
the methods used to create peak lists from raw MS or MS/MS data. 
 
– The name and version of the program used for database searching, the values of critical 
search parameters (e.g. parent ion and fragment mass tolerance, cleavage rules used, 
allowance for number of missed cleavages) and the name and version of the database(s) 
searched must be provided. 
 
– For each protein identified, measures of certainty (e.g. p-values) must be provided. For 
MS/MS, the number of peptides used to identify a protein must be given as well as the 
sequence and charge state of each peptide. For peptide mass fingerprinting, the number of 
peptides that match the sequence and the total percent of sequence coverage must be quoted. 
If extensive, the above information 
should be collected as supplementary material which is available online. 
 
– For experiments with large MS/MS data sets, estimates of the false positive rates are 
required (e.g. through searching randomised or reversed sequence databases). This 
information should be provided as supplementary material. 
 
– Where post-translational modifications are reported, the methods used to discover the 
modification must be described. The modification should be mapped to amino acid(s) by 
fragmentation analysis, but reported as ambiguous if mapping to a single amino acid is not 
possible. For isobaric modifications, evidence for assigning a specific modification must be 
provided and the spectra included as supplementary material. 
 
– Where protein sequence isoforms are reported, the peptide sequence that matches the 
unique amino acid sequence of a particular isoform must be provided. Fragmentation analysis 
of the appropriate peptides should be 
described. 
 
 
Bioinformatics 
 
– Where a manuscript describes an academic database or software, it must be either freely 
accessible via the Internet, or downloadable and the access options must be provided. This 
also applies to commercial software or databases. 
 
 
Supplementary material 
 
– Supplementary material is encouraged. This includes protein identification results, 
expression data, and mass spectrometry peak lists. Note that all data must be in processed, 
not raw, form. This material will not be published in the printed journal but will be available 
online at the PROTEOMICS website (www.proteomics-journal.com). 
